The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Placing of £1.4 million

8 Feb 2013 15:01

RNS Number : 5200X
ViaLogy PLC
08 February 2013
 

 

ViaLogy PLC ("ViaLogy" or "the Company")

 

Placing of £1.4 million

 

 

London, February 8, 2013. ViaLogy PLC (AIM: VIY), a provider of reservoir characterization, geophysical imaging and hydrocarbon sizing services to global oil and gas Exploration and Production (E&P) companies based on proprietary, patented active signal processing technology, is pleased to announce that it has today raised a total of £1,406,250 (before expenses) through the placing of 112,500,000 new ordinary shares ("the Placing Shares") at a price of 1.25p each ("the Placing") with existing and new institutional investors. As part of the Placing, for every three Placing Shares subscribed for, one warrant to subscribe for one new ordinary share at the Placing Price will be issued ("Warrant"). In aggregate, 37,500,000 Warrants have therefore been issued which can be exercised at any time until the first anniversary of issue.

 

Application has been made for the admission to trading on AIM of 112,500,000 Placing Shares, which is expected to take place on 13 February 2013.

 

The net proceeds of the Placing will be used to strengthen the balance sheet and provide additional working capital to support ViaLogy's strategy.

 

CEO, Robert W. Dean, commented "we start 2013 with a number of exciting projects including, among others, the recently announced extension of the work we are doing with Chevron, and our work in the North Sea for another client. The additional funds raised today will enable us to expand our customer reach as we secure further contracts."

 

For the purposes of the Disclosure and Transparency Rules, on admission of the first tranche of the Placing Shares, the Company's total issued share capital consists of 1,039,106,911 ordinary shares of 1 penny each.

 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

 

Options Grant

 

Under the respective terms of their employment contracts entered into on 22 June 2010, Dr. Robert Dean, ViaLogy's CEO and President and Dr. Sandeep Gulati, ViaLogy's founder and Chief Technology Officer, have today been granted option awards. Dr Dean has been awarded options over 5,538,264 shares exercisable at 1.625p per share and Dr Gulati has been awarded options over 10,456,957 shares exercisable at 1p per share.

 

 

For further information:

 

ViaLogy PLC

Terry Bond, Chairman - UK & Europe

+44 (0) 1235 834 734

Seymour Pierce (Nominated Advisor and Broker)

+44 (0) 207 107 8000

Mark Percy / Catherine Leftley (Corporate Finance)

Katie Ratner (Corporate Broking)

 

 

About ViaLogy:

ViaLogy provides reservoir characterization, geophysical imaging and hydrocarbon sizing services to global oil and gas customers based on proprietary, patented active signal processing technology. ViaLogy's QuantumRD platform assists clients in de-risking prospects over a broad range of subsurface lithologies and complex stratigraphies to generate drilling targets, position offsets and enhance recovery.

 

ViaLogy's core technology rapidly and accurately detects weak signals buried in high noise background and clutter, and is applicable to active/passive seismic, electromagnetic and magneto telluric data. By exploiting normally disregarded noise variations induced by changes in porosity, fluid presence and permeability across the formation, and adding computer-designed noise to the data, ViaLogy is able to amplify subtle noise variations to enhance areal and depth resolution in complex lithologies that are not achievable through conventional means. For more information on ViaLogy, visit www.vialogy.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLLFIEFLITIIV
Date   Source Headline
14th Dec 20217:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSNotice of Half-year results
18th Nov 20217:00 amRNSDPYD screening recommended in Spain
28th Oct 20217:00 amRNSRanger® Technology to be presented at Labroots
26th Oct 20217:00 amRNSHalf-year Trading update
29th Sep 20217:00 amRNSResult of AGM
28th Sep 20213:00 pmRNSAGM update
28th Sep 20217:00 amRNSAGM Statement
15th Sep 20217:00 amRNSShare option awards
1st Sep 20217:00 amRNSISO 15189:2012 accreditation received
1st Sep 20217:00 amRNSNotice of AGM and Annual Report 2021
19th Aug 202112:04 pmRNSCOVID-19 Surge testing contract
11th Aug 20217:01 amRNSEarn-out Milestone, Issue of Equity & TVR
11th Aug 20217:00 amRNSAudited Final results&unaudited Q1 business update
6th Aug 20217:00 amRNSConfirmation of Results Date
23rd Jul 20217:00 amRNSNotice of Results
1st Jul 202111:09 amRNSHolding(s) in Company
21st Jun 20217:00 amRNSSecond Strategic Partner for Coastal Genomics
18th Jun 20217:00 amRNSContract Award: DPYD testing kits for NHS Wales
17th Jun 20214:32 pmRNSExercise of Options
9th Jun 20217:00 amRNSMulti-year licence and supply agreement
21st May 20214:30 pmRNSDirector/PDMR Shareholding
19th May 20217:00 amRNSDistribution Partnership
18th May 20217:00 amRNSLaunch of IONA Care NIPT service offering
17th May 20217:00 amRNSFurther testing service agreement for MHC
29th Apr 20217:00 amRNSFull year Trading update
26th Apr 20217:00 amRNSFurther National Microbiology Framework awards
19th Apr 20211:21 pmRNSFurther National Microbiology Framework contract
19th Apr 20217:00 amRNSNational Framework contract award
12th Apr 20217:00 amRNSEarn-out Milestone, Issue of Equity & TVR
6th Apr 20212:43 pmRNSTesting service agreement with MyHealthCheckedplc
6th Apr 20211:54 pmRNSAgreement with Boots for COVID-19 sample kits
29th Mar 20214:00 pmRNSCOVID-19 update
23rd Mar 20217:00 amRNSShare option exercises and awards
19th Mar 20217:00 amRNSTwin Pregnancy study published using IONA® Test
17th Mar 20217:00 amRNSAppointment of VP of Sales North America
11th Mar 20217:00 amRNSYourgene Genomic Services portfolio expansion
1st Mar 20217:00 amRNSFirst US Supply Agreement
22nd Feb 20217:00 amRNSPartnership with NPH
10th Feb 202110:51 amRNSCorrection: Director / PDMR Shareholding
10th Feb 20217:00 amRNSDirector/PDMR Shareholding
8th Feb 20217:00 amRNSTrading update
13th Jan 20217:00 amRNSDPYD screening recommended in Belgium
11th Jan 20217:00 amRNSClarigene® SARS-CoV-2 Product Update
8th Jan 20217:00 amRNSIssue of Share Options
24th Dec 20207:00 amRNSCOVID-19 update
17th Dec 20207:00 amRNSHalf-year Report
15th Dec 20207:00 amRNSNotice of Half-year Results
2nd Dec 20207:00 amRNSDPYD kits recommended by NHS England
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.